Evoke Pharma Reports Third Quarter 2017 Results and Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Evoke Pharma (EVOK) Misses Q3 EPS by 14c
November 14, 2017 4:06 PM ESTEvoke Pharma (NASDAQ: EVOK) reported Q3 EPS of ($0.34), $0.14 worse than the analyst estimate of ($0.20).
As of September 30, 2017, our cash and cash equivalents were approximately $10.4 million.
For earnings history and earnings-related data on Evoke Pharma (EVOK) click here.
... More